Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
FiercePharma3d
JPM25: Bayer gears up for 'must-win battles' as Xarelto's decline is in full swing, pharma chief says
These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Bayer attacked bureaucracy by firing some 5,000 managers and asking teams to ‘self-organize.’ Here’s how it’s going after one year
Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...
Bayer to Scale Back Health Dealmaking Amid Push to Pay Down Debt
Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...
Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...
Bayer plant doch keine Pharma-Großdeals, Fokus Schuldenabbau
Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...
Wall Street Journal5d
Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...